Failure of ovarian ablation with goserelin in a pre-menopausal breast cancer patient resulting in pregnancy: a case report and review of the literature

Hill, Nicola; Madarnas, Yolanda

doi:10.1007/s10549-011-1542-y

Cited by 6 publications

(6 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…20 Perhaps, the high level of estrogen before 40-year old, which could not be suppressed completely by ovarian function suppression, may lead to more aggressive results. 20,31 What is more, young patients were more frequently diagnosed as having triple negative BC (TNBC) with a high prevalence of BRCA-1 mutations, especially younger than 40. 32,33 And there were more bone metastases than other distant recurrences observed in Chinese people with TNBC.…”

Section: Discussionmentioning

confidence: 99%

Prognostic Value of Chemotherapy-Induced Neutropenia at the First Cycle in Invasive Breast Cancer

Chen²,

Zhang³

et al. 2016

Medicine

View full text Add to dashboard Cite

Chemotherapy-induced neutropenia (CIN) was the most apparent side effects of bone marrow suppression with adjuvant chemotherapy. Recently, several studies revealed that CIN may predict better outcomes. However, the researches upon breast cancer were still indefinite.We reviewed the female patients with pathologically diagnosed invasive breast cancer at the First Affiliated Hospital of Wenzhou Medical University, between Jan 2008 and Dec 2010. The lowest neutrophil counts in the second week after the first cycle of chemotherapy were collected. Clinicopathological characteristics and survival rates were compared and analyzed between the CIN group and non-CIN group.The median follow-up time was 62 months. The differences of over-all survival and local recurrence-free survival between the 2 groups were nonsense (P = 0.938, P = 0.695, respectively). But the disease-free survival and distant metastasis-free survival of the CIN group were statically significantly better (HR = 0.391, P = 0.009, and HR = 0.315, P = 0.005, respectively). The bone metastasis-free survival may be responsible for the differences (HR = 0.469, P = 0.005). Subgroup analyses showed the CIN may predict lower bone metastases rates with ER positive status, premenopause or younger age (≤ 40) (P = 0.002, P = 0.004, and P = 0.0001, respectively). Cox analysis showed younger ages, N staging, and the presence of CIN were associated with bone metastasis-free survival independently adjusting to peritumoral vascular invasion (P < 0.05).CIN may predict a decreased recurrence risk of breast cancer, especially bone metastases.

show abstract

Section: Discussionmentioning

confidence: 99%

Prognostic Value of Chemotherapy-Induced Neutropenia at the First Cycle in Invasive Breast Cancer

Chen²,

Zhang³

et al. 2016

Medicine

View full text Add to dashboard Cite

show abstract

“…In a recent small Australian survey, half of women indicated a preference to non-pharmacological OFS but only a minority recollected this option having being discussed at diagnosis. 116 Inconvenience with monthly GnRHa injections was the main driver toward a preference for nonpharmacological methods; women should also be informed about the possible failure of pharmacological ovarian suppression, 114 the potential occurrence of pregnancy 117 and the need to use non-hormonal contraceptive methods. On the other hand, permanent menopause and potential surgical complications should be discussed in case of nonpharmacological methods, which can be the option of choice in women carrying BRCA mutations.…”

Section: Adjuvant Systemic Treatmentmentioning

confidence: 99%

ESO–ESMO 4th International Consensus Guidelines for Breast Cancer in Young Women (BCY4)

et al. 2020

View full text Add to dashboard Cite

The 4th International Consensus Conference for Breast Cancer in Young Women (BCY4) took place in October 2018, in Lugano, Switzerland, organized by the European School of Oncology (ESO) and the European Society of Medical Oncology (ESMO). Consensus recommendations for the management of breast cancer in young women were updated from BCY3 with incorporation of new evidence to inform the guidelines. Areas of research priorities were also identified. This article summarizes the ESOeESMO international consensus recommendations, which are also endorsed by the European Society of Breast Specialists (EUSOMA).

show abstract

“…A 14-week singleton pregnancy was discovered 14 months later 6 . The fourth case also presented in 2011 by Hill and et al 7 .…”

Section: Discussionmentioning

confidence: 70%

“…A 14-week singleton pregnancy was discovered 14 months later 6 . The fourth case also presented in 2011 by Hill and et al 7 . A 26-year-old woman with a clinically locally advanced right breast cancer with an estrogen receptor negative, progesterone receptor weakly positive.…”

Section: Discussionmentioning

confidence: 70%

Failure of ovarian ablation with Leuprolide acetate in a pre-menopausal breast cancer patient with metastasis resulting in pregnancy: a case report

Engın¹,

Bilir²,

Bilir³

2014

Sakarya Med J

View full text Add to dashboard Cite

Ovarian ablation was the main target of systemic therapy for breast cancer. In premenopausal women, the ovaries are the predominant source of estrogen synthesis and by this reason treatment options are oophorectomy, ovarian irradiation and luteinizing hormone releasing hormone (LHRH) analogues such as goserelin acetate (GA) and leuprolide acetate (LA) which act on the hypothalamic-pituitary-ovarian axis to suppress the hormones. Rarely these agents cannot succeed and patient may become pregnant who was under treatment of LHRH analogues. We report a premenopausal patient with breast cancer in whom ovarian ablation failed while on leuprolide acetate treatment. A 34-year-old woman was presented with bone metastatic left breast cancer. Tamoxifen 10 mg twice a day, LA 3.75mg SC every 28 days and zoledronic acid 4mg IV every 28 days were started. In May 2013, receiving LA since 7 months, the patient reported a 3-4 kg weight gain and felt movement in the abdomen due to pregnancy. To date there are 4 published case reports, patients receiving GA due to breast cancer in whom a failure in ovarian ablation. All of four cases failed after at least 15 months of treatment but our case was the earliest failure of LHRH analogues in the literature and it was failure with LA, not GA as like as the other cases. It is essential for clinicians to be aware and suggest to the patients of the potential risk of pregnancy despite using the LHRH analogs. Keywords Abstract ÖzetOlgu Sunumu / Case Report

show abstract

Failure of ovarian ablation with goserelin in a pre-menopausal breast cancer patient resulting in pregnancy: a case report and review of the literature

Cited by 6 publications

References 20 publications

Prognostic Value of Chemotherapy-Induced Neutropenia at the First Cycle in Invasive Breast Cancer

Prognostic Value of Chemotherapy-Induced Neutropenia at the First Cycle in Invasive Breast Cancer

ESO–ESMO 4th International Consensus Guidelines for Breast Cancer in Young Women (BCY4)

Failure of ovarian ablation with Leuprolide acetate in a pre-menopausal breast cancer patient with metastasis resulting in pregnancy: a case report

Contact Info

Product

Resources

About